Investigation Effect of losartan NAFLD patients

: Investigation Effect of losartan on improving liver function testes in NAFLD patients ( Non Alcoholic Fatty Liver Disease)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180412039283N1

Enrollment

250

Registered

2021-02-16

Start date

2017-12-02

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: losartan 25 mg twice a day for 12 weeks. Intervention 2: Control group: placebo 25 mg twice aday for 12 weeks.

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients with pre hypertension and fatty liver

Exclusion criteria

Exclusion criteria: history of other liver diseases except fatty liver

Design outcomes

Primary

Measure	Time frame
Liver functions tests. Timepoint: liver function tests before losartan and 12 weeks after losartan. Method of measurement: laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeghdad Sedaghat

Shahid Beheshti University of Medical Sciences

sedaghat@sbmu.ac.ir+98 21 6435 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026